Progress in oral treatment of selmesiglutide for type 2 diabetes
司美格鲁肽口服制剂治疗2型糖尿病临床研究进展

摘要

2型糖尿病（T2DM）是一种全球性的慢性代谢疾病，其患病率持续上升，给个人和社会带来沉重负担。T2DM的有效管理至关重要，以预防和延缓糖尿病相关并发症的发生发展。目前，T2DM的治疗手段主要包括生活方式干预和药物治疗，其中胰高血糖素样肽-1受体激动剂（GLP-1RA）因其良好的降糖疗效和心血管获益已成为T2DM治疗的重要组成部分。然而，传统的GLP-1RA需要注射给药，给患者依从性带来一定挑战。司美格鲁肽作为一种新型长效GLP-1RA，其口服制剂的出现为T2DM的治疗提供了新的选择。口服司美格鲁肽不仅具有与注射制剂相当的降糖疗效，还具有服用方便、患者依从性高等优势，有望改善T2DM患者的治疗体验和长期管理。本综述旨在总结口服司美格鲁肽治疗T2DM的临床研究进展，包括其药代动力学特点、降糖疗效、心血管安全性以及不良反应等，以期为临床医生和患者提供参考，促进T2DM的规范化管理。

Abstract

Type 2 diabetes mellitus (T2DM) is a global chronic metabolic disease whose prevalence continues to rise, placing a heavy burden on individuals and society. Effective management of T2DM is crucial to prevent and delay the development of diabetes-related complications. At present, the treatment of T2DM mainly includes lifestyle intervention and drug therapy, in which glucagon-like peptide-1 receptor agonist (GLP-1RA) has become an important part of the treatment of T2DM due to its good hypoglycemic efficacy and cardiovascular benefits. However, conventional GLP-1RA requires injection administration, which poses some challenges to patient compliance. The emergence of an oral formulation of simegallutide as a novel long-acting GLP-1RA provides a new option for the treatment of T2DM. Oral selmegallutide not only has the hypoglycemic effect comparable to the injection preparation, but also has the advantages of convenient taking and high patient compliance, which is expected to improve the treatment experience and long-term management of patients with T2DM. This review aims to summarize the clinical research progress of oral selmegallutide for T2DM, including its pharmacokinetic characteristics, hypoglycemic efficacy, cardiovascular safety and adverse reactions, in order to provide reference for clinicians and patients and promote the standardized management of T2DM.